Table 3.1 Applications of derivatives of porphyrin and phthalocyanine labeled with different
metallic radioisotopes
Compound
Radioisotope Half-life
Application
References
Porphyrin
57
Co
271.8 days
Tumor detection
[24]
Porphyrin
64
Cu
12.7 h
PET/CT
[15]
Porphyrin
64
Cu
12.7 h
Tumor detection
[27]
Porphyrin
64
Cu
12.7 h
PET
[31]
Porphyrin
64
Cu
12.7 h
Synthesis of bimodal
imaging agents
[85]
Porphyrin
64
Cu
12.7 h
PET
[32]
Phthalocyanine
64
Cu
12.7 h
PET
[80]
Phthalocyanine
64
Cu
12.7 h
PET
[17]
Porphyrin
188
Re
16.98 h
Radionuclide therapy
[79]
Porphyrin
10
B
(known to be stable)
Boron neutron capture
therapy (BNCT)
[86]
Porphyrin
111
In
2.80 days
Tumor imaging
[87]
Porphyrin
111
In
2.80 days
Cancer detection
[88]
Porphyrin
111
In
2.80 days
Labeling HPD
[89]
Porphyrin
111
In
2.80 days
Tumor detection
[65]
Porphyrin
111
In
2.80 days
Tumor detection
[67]
Porphyrin
111
In
2.80 days
Imaging of lymph
nodes
[66]
Porphyrin
111
In
2.80 days
Monoclonal antibody
labelling
[69]
Porphyrin
186/188
Re
186
Re(t 1/2 = 90 h),
188
Re(t 1/2 = 16.9 h)
Tumor radiotherapy
[76]
Porphyrin
67
Ga
78.26 h
SPECT
[45]
Porphyrin
68
Ga
271 days
PET
[47]
Porphyrin
68
Ga
271 days
PET
[48]
Porphyrin
68
Ga
271 days
SPECT
[45]
Porphyrin
67
Ga
78.26 h
Human melanoma
detection
[90]
Phthalocyanine
67
Ga
78.26 h
PDT
[10]
Porphyrin
99m
Tc
6 h
Tumor imaging
[57]
Porphyrin
99m
Tc
6 h
Fluorescent imaging
for tumor detection
[60]
Porphyrin
99m
Tc
6 h
Tumor localization
[55]
Porphyrin
99m
Tc
6 h
Tumor imaging and
diagnosis
[59]
Porphyrin
99m
Tc
6 h
Tumor imaging
[59]
Porphyrin
140
Nd
3.37 days
Tumor therapy; PET
[71]
Porphyrin
18
F
109.77 min
Tumor detection
[91]
Porphyrin
18
F
109.77 min
PDT/PET
[92]
Phthalocyanine
65
Zn
244.26 days
PDT
[82]
(continued)
54
V. Rajendiran et al.
metallic radioisotopes
Compound
Radioisotope Half-life
Application
References
Porphyrin
57
Co
271.8 days
Tumor detection
[24]
Porphyrin
64
Cu
12.7 h
PET/CT
[15]
Porphyrin
64
Cu
12.7 h
Tumor detection
[27]
Porphyrin
64
Cu
12.7 h
PET
[31]
Porphyrin
64
Cu
12.7 h
Synthesis of bimodal
imaging agents
[85]
Porphyrin
64
Cu
12.7 h
PET
[32]
Phthalocyanine
64
Cu
12.7 h
PET
[80]
Phthalocyanine
64
Cu
12.7 h
PET
[17]
Porphyrin
188
Re
16.98 h
Radionuclide therapy
[79]
Porphyrin
10
B
(known to be stable)
Boron neutron capture
therapy (BNCT)
[86]
Porphyrin
111
In
2.80 days
Tumor imaging
[87]
Porphyrin
111
In
2.80 days
Cancer detection
[88]
Porphyrin
111
In
2.80 days
Labeling HPD
[89]
Porphyrin
111
In
2.80 days
Tumor detection
[65]
Porphyrin
111
In
2.80 days
Tumor detection
[67]
Porphyrin
111
In
2.80 days
Imaging of lymph
nodes
[66]
Porphyrin
111
In
2.80 days
Monoclonal antibody
labelling
[69]
Porphyrin
186/188
Re
186
Re(t 1/2 = 90 h),
188
Re(t 1/2 = 16.9 h)
Tumor radiotherapy
[76]
Porphyrin
67
Ga
78.26 h
SPECT
[45]
Porphyrin
68
Ga
271 days
PET
[47]
Porphyrin
68
Ga
271 days
PET
[48]
Porphyrin
68
Ga
271 days
SPECT
[45]
Porphyrin
67
Ga
78.26 h
Human melanoma
detection
[90]
Phthalocyanine
67
Ga
78.26 h
PDT
[10]
Porphyrin
99m
Tc
6 h
Tumor imaging
[57]
Porphyrin
99m
Tc
6 h
Fluorescent imaging
for tumor detection
[60]
Porphyrin
99m
Tc
6 h
Tumor localization
[55]
Porphyrin
99m
Tc
6 h
Tumor imaging and
diagnosis
[59]
Porphyrin
99m
Tc
6 h
Tumor imaging
[59]
Porphyrin
140
Nd
3.37 days
Tumor therapy; PET
[71]
Porphyrin
18
F
109.77 min
Tumor detection
[91]
Porphyrin
18
F
109.77 min
PDT/PET
[92]
Phthalocyanine
65
Zn
244.26 days
PDT
[82]
(continued)
54
V. Rajendiran et al.
